SE445013B - Medel for att forebygga eller behandla infektioner hos menniskor och djur - Google Patents
Medel for att forebygga eller behandla infektioner hos menniskor och djurInfo
- Publication number
- SE445013B SE445013B SE7905523A SE7905523A SE445013B SE 445013 B SE445013 B SE 445013B SE 7905523 A SE7905523 A SE 7905523A SE 7905523 A SE7905523 A SE 7905523A SE 445013 B SE445013 B SE 445013B
- Authority
- SE
- Sweden
- Prior art keywords
- groups
- polymer
- hydrophobic
- water
- infections
- Prior art date
Links
- 208000015181 infectious disease Diseases 0.000 title claims description 10
- 241001465754 Metazoa Species 0.000 title claims description 4
- 229920000642 polymer Polymers 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 17
- 125000001165 hydrophobic group Chemical group 0.000 claims description 16
- 239000002245 particle Substances 0.000 claims description 16
- 150000004676 glycans Chemical class 0.000 claims description 14
- 229920001282 polysaccharide Polymers 0.000 claims description 12
- 239000005017 polysaccharide Substances 0.000 claims description 12
- 125000004432 carbon atom Chemical group C* 0.000 claims description 9
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 230000000968 intestinal effect Effects 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 description 15
- 241000894006 Bacteria Species 0.000 description 13
- 229920000936 Agarose Polymers 0.000 description 10
- 125000001424 substituent group Chemical group 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 230000001588 bifunctional effect Effects 0.000 description 7
- 239000003431 cross linking reagent Substances 0.000 description 7
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- 238000004132 cross linking Methods 0.000 description 6
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 238000006467 substitution reaction Methods 0.000 description 6
- 239000004593 Epoxy Substances 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 239000000460 chlorine Substances 0.000 description 4
- 239000007863 gel particle Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 238000003776 cleavage reaction Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 230000007017 scission Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000004971 Cross linker Substances 0.000 description 2
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- -1 arabinanes Polymers 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 238000009739 binding Methods 0.000 description 2
- 238000012662 bulk polymerization Methods 0.000 description 2
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical group OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000012847 fine chemical Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 150000002772 monosaccharides Chemical group 0.000 description 2
- 150000004804 polysaccharides Polymers 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- DEWLEGDTCGBNGU-UHFFFAOYSA-N 1,3-dichloropropan-2-ol Chemical compound ClCC(O)CCl DEWLEGDTCGBNGU-UHFFFAOYSA-N 0.000 description 1
- GUPXYSSGJWIURR-UHFFFAOYSA-N 3-octoxypropane-1,2-diol Chemical compound CCCCCCCCOCC(O)CO GUPXYSSGJWIURR-UHFFFAOYSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 241000723347 Cinnamomum Species 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 229920001503 Glucan Polymers 0.000 description 1
- 229920000057 Mannan Polymers 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- GKIPXFAANLTWBM-UHFFFAOYSA-N epibromohydrin Chemical compound BrCC1CO1 GKIPXFAANLTWBM-UHFFFAOYSA-N 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 238000006266 etherification reaction Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 150000003944 halohydrins Chemical class 0.000 description 1
- ARBOVOVUTSQWSS-UHFFFAOYSA-N hexadecanoyl chloride Chemical compound CCCCCCCCCCCCCCCC(Cl)=O ARBOVOVUTSQWSS-UHFFFAOYSA-N 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000008991 intestinal motility Effects 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical group O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- RAFYDKXYXRZODZ-UHFFFAOYSA-N octanoyl octanoate Chemical compound CCCCCCCC(=O)OC(=O)CCCCCCC RAFYDKXYXRZODZ-UHFFFAOYSA-N 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 229930195734 saturated hydrocarbon Chemical group 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000010557 suspension polymerization reaction Methods 0.000 description 1
- 239000001974 tryptic soy broth Substances 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229920003176 water-insoluble polymer Polymers 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229920001221 xylan Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7905523A SE445013B (sv) | 1979-06-21 | 1979-06-21 | Medel for att forebygga eller behandla infektioner hos menniskor och djur |
| DE8080103218T DE3071708D1 (en) | 1979-06-21 | 1980-06-10 | An agent for preventing or treating infections in human beings and animals |
| EP80103218A EP0021230B2 (en) | 1979-06-21 | 1980-06-10 | An agent for preventing or treating infections in human beings and animals |
| CA000354527A CA1146865A (en) | 1979-06-21 | 1980-06-20 | Agent for preventing or treating infections in human beings and animals |
| JP8346880A JPS567719A (en) | 1979-06-21 | 1980-06-21 | Drug for prevention and remedy of infection |
| US06/575,160 US4645757A (en) | 1979-06-21 | 1984-01-30 | Agent for preventing or treating infections in human beings and animals |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE7905523A SE445013B (sv) | 1979-06-21 | 1979-06-21 | Medel for att forebygga eller behandla infektioner hos menniskor och djur |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7905523L SE7905523L (sv) | 1980-12-22 |
| SE445013B true SE445013B (sv) | 1986-05-26 |
Family
ID=20338361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7905523A SE445013B (sv) | 1979-06-21 | 1979-06-21 | Medel for att forebygga eller behandla infektioner hos menniskor och djur |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US4645757A (enExample) |
| EP (1) | EP0021230B2 (enExample) |
| JP (1) | JPS567719A (enExample) |
| CA (1) | CA1146865A (enExample) |
| DE (1) | DE3071708D1 (enExample) |
| SE (1) | SE445013B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8204244L (sv) * | 1982-07-09 | 1984-01-10 | Ulf Schroder | Kristalliserad kolhydratsmatris for biologiskt aktiva substanser |
| SE460017B (sv) * | 1984-03-14 | 1989-09-04 | Landstingens Inkopscentral | Bakterieadsorberande komposition i vattenoloeslig form |
| US5189015A (en) * | 1984-05-30 | 1993-02-23 | Alfa-Laval Agri International Ab | Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability |
| SE8801894D0 (sv) * | 1988-05-20 | 1988-05-20 | Alfa Laval Agri Int | Fibronektinbindande protein |
| SE8901687D0 (sv) * | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | Fibronectin binding protein as well as its preparation |
| US5281414A (en) * | 1989-07-28 | 1994-01-25 | Stockel Richard F | Three-dimensional water disinfectants |
| JP2911554B2 (ja) * | 1990-06-25 | 1999-06-23 | 台糖株式会社 | 抗ウィルス剤 |
| US5440014A (en) * | 1990-08-10 | 1995-08-08 | H+E,Uml/Oo/ K; Magnus | Fibronectin binding peptide |
| JPH0751209B2 (ja) * | 1991-06-06 | 1995-06-05 | ベステクス株式会社 | フィルタ材の製造方法 |
| US5980908A (en) * | 1991-12-05 | 1999-11-09 | Alfa Laval Ab | Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment |
| TW438608B (en) * | 1995-08-02 | 2001-06-07 | Hisamitsu Pharmaceutical Co | A tablet containing anion exchange resin |
| DE19631421C2 (de) | 1996-08-06 | 2002-07-18 | Beiersdorf Ag | Antimikrobielle Wundauflagen |
| JP4010585B2 (ja) * | 1996-10-15 | 2007-11-21 | 久光製薬株式会社 | 陰イオン交換樹脂を含有する錠剤 |
| US8519008B2 (en) | 2003-01-22 | 2013-08-27 | Purina Animal Nutrition Llc | Method and composition for improving the health of young monogastric mammals |
| ES2350483T3 (es) * | 2003-06-13 | 2011-01-24 | Wadström, Torkel | Producto con fines de absorción. |
| DE102004035905A1 (de) * | 2004-07-20 | 2006-02-16 | Biotronik Vi Patent Ag | Magnesiumhaltiges Wundauflagematerial |
| US9463119B2 (en) | 2007-01-18 | 2016-10-11 | Abigo Medical Ab | Wound dressing with a bacterial adsorbing composition and moisture holding system |
| EP2498820B1 (en) * | 2009-11-13 | 2019-01-09 | University of Maryland, College Park | Advanced functional biocompatible foam used as a hemostatic agent for compressible and non-compressible acute wounds |
| WO2013015738A1 (en) | 2011-07-22 | 2013-01-31 | HJERTÉN, Maria | Capture of pathogenic and non-pathogenic biopolymers and bioparticles |
| WO2015077742A2 (en) * | 2013-11-25 | 2015-05-28 | University Of Maryland, Office Of Technology Commercialization | Quick-drying, tacky polymer film compositions and methods of use |
| EP3934659A4 (en) | 2019-03-05 | 2022-12-14 | Medcura, Inc. | SYSTEM AND METHOD FOR REDUCING TISSUE OR ORGAN ADHESION |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB386067A (en) * | 1931-01-03 | 1933-01-12 | Le Carbone Sa | Improvements in or relating to dressings |
| NL255047A (enExample) * | 1959-08-21 | |||
| US3130126A (en) * | 1962-09-14 | 1964-04-21 | Central Pharmacal Company | Oral pharmaceutical products prepared with carboxymethyl benzyl dextran having a low carboxymethyl d. s. of 0.15 |
| US3224941A (en) * | 1963-01-21 | 1965-12-21 | Lilly Co Eli | Resin compositions and method for controlling diarrhea |
| GB1090421A (en) * | 1963-12-13 | 1967-11-08 | Aerosan Ltd | Improvements in surgical dressings |
| US3545442A (en) * | 1964-09-23 | 1970-12-08 | Huyck Corp | Bandaging and dressing material |
| FR5705M (enExample) * | 1966-08-31 | 1968-01-15 | ||
| US3489148A (en) * | 1966-12-20 | 1970-01-13 | Procter & Gamble | Topsheet for disposable diapers |
| US3624209A (en) * | 1966-12-28 | 1971-11-30 | Bristol Myers Co | Composition for treatment of gastro-intestinal disorders |
| FR6901M (enExample) * | 1967-06-23 | 1969-04-28 | ||
| US3903268A (en) * | 1968-02-12 | 1975-09-02 | Lescarden Ltd | Chitin and chitin derivatives for promoting wound healing |
| FR2077687B1 (enExample) * | 1970-02-05 | 1973-03-16 | Roussel Uclaf | |
| US3911116A (en) * | 1970-04-13 | 1975-10-07 | Leslie L Balassa | Process for promoting wound healing with chitin derivatives |
| US3914413A (en) * | 1971-02-10 | 1975-10-21 | Leslie L Balassa | Process for facilitating wound healing with N-acetylated partially depolymerized chitin materials |
| US3943247A (en) * | 1972-05-22 | 1976-03-09 | Kaken Kagaku Kabushiki Kaisha | Treatment of bacterial infections with glucan compositions |
| SE452109B (sv) * | 1973-01-29 | 1987-11-16 | Pharmacia Ab | Rengoringsmedel for vetskande utvertes sarytor |
| SE413986B (sv) * | 1973-03-23 | 1980-07-07 | Exploaterings Ab Tbf | Sett att separera amfipatiska emnen innehallande bade hydrofila och hydrofoba grupper samt gelprodukt for genomforande av separationen |
| FR2244543B1 (enExample) * | 1973-07-27 | 1977-07-01 | Inst Nl Sante Rech Medica | |
| US3965263A (en) * | 1973-09-28 | 1976-06-22 | The Purdue Frederick Company | Choline salicylate compositions and methods for achieving analgesia |
| US4002173A (en) * | 1974-07-23 | 1977-01-11 | International Paper Company | Diester crosslinked polyglucan hydrogels and reticulated sponges thereof |
| NL159285B (nl) * | 1975-01-24 | 1979-02-15 | Tevic Int Bv | Vochtabsorberend produkt, voorzien van een laag vochtabsorberend materiaal en een vochtdoorlatende deklaag. |
| GB1541435A (en) * | 1975-02-04 | 1979-02-28 | Searle & Co | Immunological materials |
| GB1544908A (en) * | 1975-07-08 | 1979-04-25 | Chembiomed Ltd | Artificial oligosaccharide antigenic determinants |
| SE7702261L (sv) * | 1976-03-02 | 1977-09-07 | Pharmaco Inc | Forfarande for att immobilisera antimikrobiella emnen |
| JPS5446841A (en) * | 1977-08-16 | 1979-04-13 | Wellcome Found | Drug substituted hapten substance and production thereof |
| US4241054A (en) * | 1978-12-08 | 1980-12-23 | The Procter & Gamble Company | Detoxifying lipophilic toxins |
-
1979
- 1979-06-21 SE SE7905523A patent/SE445013B/sv unknown
-
1980
- 1980-06-10 DE DE8080103218T patent/DE3071708D1/de not_active Expired
- 1980-06-10 EP EP80103218A patent/EP0021230B2/en not_active Expired - Lifetime
- 1980-06-20 CA CA000354527A patent/CA1146865A/en not_active Expired
- 1980-06-21 JP JP8346880A patent/JPS567719A/ja active Granted
-
1984
- 1984-01-30 US US06/575,160 patent/US4645757A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| SE7905523L (sv) | 1980-12-22 |
| EP0021230B2 (en) | 1990-07-25 |
| JPH0152370B2 (enExample) | 1989-11-08 |
| CA1146865A (en) | 1983-05-24 |
| EP0021230A2 (en) | 1981-01-07 |
| DE3071708D1 (en) | 1986-09-25 |
| US4645757A (en) | 1987-02-24 |
| EP0021230B1 (en) | 1986-08-20 |
| JPS567719A (en) | 1981-01-27 |
| EP0021230A3 (en) | 1981-01-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SE445013B (sv) | Medel for att forebygga eller behandla infektioner hos menniskor och djur | |
| Chen et al. | Progress in research of chitosan chemical modification technologies and their applications | |
| Yin et al. | Development of inherently antibacterial, biodegradable, and biologically active chitosan/pseudo-protein hybrid hydrogels as biofunctional wound dressings | |
| Bhattacharyya et al. | Carbon dot cross-linked gelatin nanocomposite hydrogel for pH-sensing and pH-responsive drug delivery | |
| Gomez d’Ayala et al. | Marine derived polysaccharides for biomedical applications: chemical modification approaches | |
| Jain et al. | A new horizon in modifications of chitosan: syntheses and applications | |
| KR100314488B1 (ko) | 다당류겔조성물 | |
| Jennings et al. | Chitosan Based Biomaterials Volume 1: Fundamentals | |
| Sahiner et al. | Polyethyleneimine modified poly (Hyaluronic acid) particles with controllable antimicrobial and anticancer effects | |
| Zhang et al. | Polymer–antibiotic conjugates as antibacterial additives in dental resins | |
| Kundu et al. | Carboxymethyl cellulose–xylan hydrogel: synthesis, characterization, and in vitro release of vitamin B12 | |
| Aminabhavi et al. | Production of chitosan-based hydrogels for biomedical applications | |
| WO2018030631A1 (ko) | 가시광선 광경화 수용성 키토산 유도체, 키토산 하이드로겔 및 이의 제조방법 | |
| Wang et al. | Facile fabrication of bactericidal and antifouling switchable chitosan wound dressing through a ‘click’-type interfacial reaction | |
| Gao et al. | Construction of Antibacterial N‐Halamine Polymer Nanomaterials Capable of Bacterial Membrane Disruption for Efficient Anti‐Infective Wound Therapy | |
| Nath et al. | Multifunctional mussel‐inspired Gelatin and Tannic acid‐based hydrogel with pH‐controllable release of vitamin B12 | |
| Alsaady et al. | The synergistic effects of chitosan-alginate nanoparticles loaded with doxycycline antibiotic against multidrug resistant proteus mirabilis, Escherichia coli and enterococcus faecalis | |
| Badawy et al. | Chitosan and its modifications as biologically active compounds in different applications | |
| Chauhan | Biocidal polymers | |
| CN112358635A (zh) | 一种聚乙烯醇基水凝胶膜及其制备方法 | |
| JP2018145170A (ja) | エモジンを担持するためのナノ粒子の新規な調製方法 | |
| Wong et al. | Grafted copolymerized chitosan and its applications as a green biopolymer | |
| Sahoo et al. | Chitosan: The most valuable derivative of chitin | |
| Shameli et al. | Cross-linked Chitosan-Based Hydrogels Nanocomposites for Treatment of Disease | |
| CN111269367A (zh) | 一种酸响应电荷屏蔽纳米粒子及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 7905523-2 Format of ref document f/p: F |